Belfast-based Contract Research Organisation (CRO) Fusion Antibodies (AIM: FAB) announced on Tuesday that it has entered into a collaboration agreement with the National Cancer Institute (NCI), utilising its OptiMAL technology for discovering novel antibodies against cancer targets.
The partnership spans up to two years, with Fusion granting NCI access to OptiMAL for validating the technology in NCI's laboratories. Successful results will be jointly published and NCI will retain identified antibodies.
NCI, a key cancer research and training agency under the US National Institutes of Health, aims to leverage Fusion's expertise in pre-clinical antibody discovery for potential therapeutic applications.
Fusion Antibodies specialises in antibody engineering for therapeutic drug and diagnostic uses. The company provides a range of services, including antibody design, production, purification, sequencing and humanisation. With a mission to facilitate timely and cost-effective product development, Fusion Antibodies has a global client base, including top pharmaceutical companies.
The company's growth strategy involves leveraging technological advances and scientific innovations to expedite drug development processes. The collaboration aligns with Fusion's commitment to advancing healthcare solutions in a dynamic market, with the global monoclonal antibody therapeutics market projected to exceed USD445bn by 2028.
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Royalty Pharma acquires RYTELO royalty interest from Geron
Minghui Pharmaceutical announces initial MHB039A Phase I clinical trial results
REGENXBIO reports reduced net loss for nine months to September 2024
Sanofi's Dupixent approved for young children with eosinophilic esophagitis
Research Grid raises USD6.5m seed round
Duoning Biotechnology partners with Branca Bunus on transfection reagents
Intra-Cellular Therapies' CAPLYTA shows promise in preventing schizophrenia relapse
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis